Literature DB >> 11235991

Vascular endothelial growth factor family members are differentially regulated by c-erbB signaling in head and neck squamous carcinoma cells.

P O-charoenrat1, P Rhys-Evans, H Modjtahedi, S A Eccles.   

Abstract

Aberrant expression of tyrosine kinases such as c-erbB and EGFR contributes to the progression of head and neck squamous cell carcinomas (HNSCCs). One mechanism may be potentiation of angiogenesis, since upregulation of vascular endothelial growth factor (VEGF) expression by activation of epidermal growth factor receptor (EGFR) and/or c-erbB-2 has been described. Firstly, we demonstrated expression of all 4 members of the VEGF family in a panel of 15 HNSCC cell lines which over-express one or more c-erbB receptors. We then explored the regulatory roles of three major ligands with different selectivity of binding to c-erbB receptors (namely transforming growth factor-alpha (TGF-alpha), betacellulin (BTC) and heregulin-beta1 (HRG-beta1)) on VEGF-A, B, C and D expression in selected HNSCC lines. Using semi-quantitative reverse transcription-PCR, we showed that all three c-erbB ligands up-regulated VEGF-A mRNA (all isoforms) and VEGF-C (BTC max at 1-10 nM; TGF-alpha and HRG-beta1 max at 10-100 nM) but had no effect on VEGF-B. Interestingly, all ligands simultaneously down-regulated the expression of VEGF-D mRNA. A monoclonal antibody (mAb) which blocks EGFR ligand binding (ICR62) down-regulated the basal levels of VEGF-A (all isoforms) and VEGF-C, had no detectable effects on VEGF-B and increased VEGF-D. ICR62 also reversed the effects of all three erbB ligands (TGF-alpha, BTC and HRG-beta1) on VEGF-A, VEGF-C and VEGF-D expression. An anti-c-erbB-2 mAb (ICR12) showed similar effects on basal or ligand-modulated expression of VEGF in these cell lines, although to a lesser extent. Our results reveal that the four VEGF genes are regulated by c-erbB signaling pathways in a strikingly different manner, suggesting that they serve distinct, although perhaps complimentary (VEGF-A and VEGF-C) or antagonistic (VEGF-D) functions. The EGFR and c-erbB-2 signaling pathway(s) plays a role in VEGF regulation in HNSCC, although EGFR would appear to be dominant in this cell type.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11235991     DOI: 10.1023/a:1006764100867

Source DB:  PubMed          Journal:  Clin Exp Metastasis        ISSN: 0262-0898            Impact factor:   5.150


  27 in total

1.  Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice.

Authors:  P Perrotte; T Matsumoto; K Inoue; H Kuniyasu; B Y Eve; D J Hicklin; R Radinsky; C P Dinney
Journal:  Clin Cancer Res       Date:  1999-02       Impact factor: 12.531

2.  Transforming growth factor-alpha-induced transcriptional activation of the vascular permeability factor (VPF/VEGF) gene requires AP-2-dependent DNA binding and transactivation.

Authors:  J Gille; R A Swerlick; S W Caughman
Journal:  EMBO J       Date:  1997-02-17       Impact factor: 11.598

Review 3.  Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis.

Authors:  D Hanahan; J Folkman
Journal:  Cell       Date:  1996-08-09       Impact factor: 41.582

4.  Expression of vascular endothelial growth factors A, B, C, and D and their relationships to lymph node status in lung adenocarcinoma.

Authors:  T Niki; S Iba; M Tokunou; T Yamada; Y Matsuno; S Hirohashi
Journal:  Clin Cancer Res       Date:  2000-06       Impact factor: 12.531

Review 5.  Biochemical and clinical implications of the ErbB/HER signaling network of growth factor receptors.

Authors:  L N Klapper; M H Kirschbaum; M Sela; Y Yarden
Journal:  Adv Cancer Res       Date:  2000       Impact factor: 6.242

6.  Identification of a c-fos-induced gene that is related to the platelet-derived growth factor/vascular endothelial growth factor family.

Authors:  M Orlandini; L Marconcini; R Ferruzzi; S Oliviero
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-15       Impact factor: 11.205

7.  VEGFR-3 and its ligand VEGF-C are associated with angiogenesis in breast cancer.

Authors:  R Valtola; P Salven; P Heikkilä; J Taipale; H Joensuu; M Rehn; T Pihlajaniemi; H Weich; R deWaal; K Alitalo
Journal:  Am J Pathol       Date:  1999-05       Impact factor: 4.307

8.  Overexpression of epidermal growth factor receptor in human head and neck squamous carcinoma cell lines correlates with matrix metalloproteinase-9 expression and in vitro invasion.

Authors:  P O-Charoenrat; P Rhys-Evans; H Modjtahedi; W Court; G Box; S Eccles
Journal:  Int J Cancer       Date:  2000-05-01       Impact factor: 7.396

9.  Isolation of a human placenta cDNA coding for a protein related to the vascular permeability factor.

Authors:  D Maglione; V Guerriero; G Viglietto; P Delli-Bovi; M G Persico
Journal:  Proc Natl Acad Sci U S A       Date:  1991-10-15       Impact factor: 11.205

10.  Vascular endothelial growth factor B, a novel growth factor for endothelial cells.

Authors:  B Olofsson; K Pajusola; A Kaipainen; G von Euler; V Joukov; O Saksela; A Orpana; R F Pettersson; K Alitalo; U Eriksson
Journal:  Proc Natl Acad Sci U S A       Date:  1996-03-19       Impact factor: 11.205

View more
  19 in total

1.  High vascular endothelial growth factor gene expression predicts poor outcome in patients with non-luminal A breast cancer.

Authors:  Doonyapat Sa-Nguanraksa; Tuenjai Chuangsuwanich; Tawatchai Pongpruttipan; Pornchai O-Charoenrat
Journal:  Mol Clin Oncol       Date:  2015-06-09

2.  Differential regulation of tumor angiogenesis by distinct ErbB homo- and heterodimers.

Authors:  Lily Yen; Naciba Benlimame; Zeng-Rong Nie; Dingzhang Xiao; Taiqi Wang; Ala-Eddin Al Moustafa; Hiroyasu Esumi; Julie Milanini; Nancy E Hynes; Gilles Pages; Moulay A Alaoui-Jamali
Journal:  Mol Biol Cell       Date:  2002-11       Impact factor: 4.138

Review 3.  Targeting the epidermal growth factor receptor in the treatment of colorectal cancer: state of the art.

Authors:  Robert B Diasio; Jeanne Fourie
Journal:  Drugs       Date:  2006       Impact factor: 9.546

Review 4.  Breast cancer in the clinic: treatments past, treatments future.

Authors:  G W Sledge
Journal:  J Mammary Gland Biol Neoplasia       Date:  2001-10       Impact factor: 2.673

Review 5.  EGFR(s) in aging and carcinogenesis of the gastrointestinal tract.

Authors:  Jyoti Nautiyal; Shailender Singh Kanwar; Adhip P N Majumdar
Journal:  Curr Protein Pept Sci       Date:  2010-09       Impact factor: 3.272

Review 6.  Lymphatic metastasis in breast cancer: importance and new insights into cellular and molecular mechanisms.

Authors:  Suzanne Eccles; Lenaic Paon; Jonathan Sleeman
Journal:  Clin Exp Metastasis       Date:  2007-11-06       Impact factor: 5.150

7.  Transforming growth factor-β1 downregulates vascular endothelial growth factor-D expression in human lung fibroblasts via the Jun NH2-terminal kinase signaling pathway.

Authors:  Ye Cui; Juan C Osorio; Cristobal Risquez; Hao Wang; Ying Shi; Bernadette R Gochuico; Danielle Morse; Ivan O Rosas; Souheil El-Chemaly
Journal:  Mol Med       Date:  2014-03-20       Impact factor: 6.354

Review 8.  Molecular biology of head and neck cancer: risks and pathways.

Authors:  Michael E Stadler; Mihir R Patel; Marion E Couch; David Neil Hayes
Journal:  Hematol Oncol Clin North Am       Date:  2008-12       Impact factor: 3.722

9.  VEGF-D expression correlates with colorectal cancer aggressiveness and is downregulated by cetuximab.

Authors:  Markus Moehler; Christian Frings; Annett Mueller; Ines Gockel; Carl-C Schimanski; Stefan Biesterfeld; Peter-R Galle; Martin-H Holtmann
Journal:  World J Gastroenterol       Date:  2008-07-14       Impact factor: 5.742

10.  Immunotherapy of head and neck cancer: current and future considerations.

Authors:  Alexander D Rapidis; Gregory T Wolf
Journal:  J Oncol       Date:  2009-08-09       Impact factor: 4.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.